I am going to share my recent emails with GZ here against my better judgment (I’m the one who GZ expressed frustration to about the length of time the MHRA was taking a couple months ago).
I realize that this isn’t much new “information,” but I hope it helps the REAL INVESTORS on here who are interested in actual company correspondence, rather than mindless bashing and pumping.
For those folks, I’d be interested in your opinions on approval timing, and the chance of conditional approval versus full approval. For me, I am nearly certain that there will not be a rejection, that approval will be for manual manufacturing only, and that approval will be for GBM/RGBM only, so IMO there is no need to relitigate those issues.
* NOTE THAT THE ALL CAPS HAVE BEEN ADDED BY ME FOR EMPHASIS.
—
Hi Jake,
We have communicated something positive recently – WE’RE SETTING UP THE LEUKOPHERESIS UNIT IN LONDON in preparation of MHRA approval, whenever that happens.
Stay tuned for MORE POSITIVE DEVELOPMENTS IN THE NEXT FEW WEEKS AND MONTHS.
I don’t understand why retail investors believe we can do something about the way the market makers manipulate our stock.
THEY HAVE A MIND OF THEIR OWN AND ACT ACCORDINGLY.
To try and do anything is a waste of valuable time that we are using instead to advance the company’s objectives.
And I’m sorry I haven’t been more prompt in my responses, but you know I have other responsibilities here at NWBO.
Last week I was in San Diego for AACR annual meeting networking and meeting with people who will be able to collaborate with us and who are our supporters.
Then I had meetings in NY city for the same reasons.
TO SPECIFICALLY ANSWER YOUR QUESTIONS BELOW:
NO. The licensing of the leukopheresis unit is NOT part of the review process.
However, it’s likely that the MHRA reviewers have learned about it since it was disclosed in a PR.
NO. Many drugs and especially almost all cell therapies are manufactured in one place.
It is expensive to set up multiple manufacturing facilities and to train more lab people, especially before regulatory approval.
Although we are planning to do this IN THE FUTURE IN NORTH AMERICA when resources permit.
THE COMPANY HAD ALWAYS BELIEVED THAT DCVax-L WILL BE APPROVED.
Whether it’s a full or conditional approval remains to be determined, but either way it will enable us to launch DCVax-L in the U.K.
I hope this helps.
Cheers, George
From: Jake
Sent: Monday, April 27, 2026 2:51 PM
To: George
Subject: Re: 11 Years of Supporting this Company
I know you’re probably very busy and I don’t mean to bother you, but the lack of replies and the price action today are ABSOLUTELY TERRIFYING.
I’m up to 3,333,000 SHARES and am begging you guys to communicate something positive to investors.
On Mon, Apr 27, 2026 at 7:54 AM Jake wrote:
George, what is going on?
WE’RE DOWN 30% FROM THIS MORNING.
This is just demoralizing.
Are you feeling frustrated or confident?
On Tue, Apr 21, 2026 at 10:24 AM Jake wrote:
Hi George,
I am doing my best to remain patient, but am demoralized by the reaction to today’s seemingly good news.
Could you please briefly answer the following questions:
1. DO YOU CONSIDER THE LICENSING OF THE LEUKAPHERESIS CLINIC TO BE PART OF THE MAA REVIEW PROCESS?
2. IN YOUR OPINION, COULD THE COMPANY'S RELIANCE ON A SINGLE MANUFACTURING SITE WITHOUT ESTABLISHED CONTINGENCY PLANS AFFECT THE MAA APPROVAL?
3. SHOULD INVESTORS INTERPRET CURRENT MANUFACTURING AND LAUNCH READINESS AS BEING ALIGNED WITH A FULL APPROVAL SCENARIO?
Thanks,
Jake
Bullish
Market Data 
Markets 
AI
